Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05008055
Recruitment Status : Recruiting
First Posted : August 17, 2021
Last Update Posted : June 13, 2022
Information provided by (Responsible Party):

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : November 2, 2023
Estimated Study Completion Date : November 2, 2023